A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial

Official title: A Phase 1, Open Label, Randomized, Crossover Study Evaluating the Relative Bioavailability and Food Effect of a VX-147 Test Tablet Formulation Compared to a Reference Tablet Formulation in Healthy Adult Subjects

Status Completed

Clinical Trial Summary

The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.

Clinical Trial Description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.). ;

Related Conditions & MeSH terms

• Focal Segmental Glomerulosclerosis (FSGS)
• Glomerulosclerosis, Focal Segmental

• NCT number: NCT05955872
• Study type: Interventional
• Source: Vertex Pharmaceuticals Incorporated
• Status: Completed
• Phase: Phase 1
• Start date: July 19, 2023
• Completion date: September 2, 2023